塩酸イリノテカン単剤の治療成績

摘要

イリノテカン単剤の肺癌に対する化学療法は90年代に多くの検討がなされた．単剤の来治療進行非小細胞肺癌に対するoverallの奏効率は265例による検討で24.5％，生存期間中央値は6.2～10.8か月であった．毒性はgrade3/4が白血球減少（25％），好中球減少（29％），下痢（21％），嘔気/嘔吐（22％）であった．特に下痢が問題になった．小細胞肺癌に対する単剤治療はほとhどが既治療例に対するものoverallの奏効率は118例による検討で17.6％，生存期間中央値は4.0～6.1か月であった．今後は非小細胞肺癌/小細胞肺癌の再発例の治療に対しさらなる検討が行われるべきであろう．During the 1990 's many irinotecan monotherapy trials for lung cancer were conducted. Irinotecan monotherapy against previously untreated advanced non-small cell lung cancer showed an overall response rate of 24.5% and median survival time of 6.2 to 10.8 months in 265 patients. There were grade 3 or 4 toxicity of leukopenia (25%), neutropenia (29%), diarrhea (21%), nausea/vomiting (22%) in the treatments. Diarrhea was an especially serious problem. In small cell lung cancer, most patients had been previously treated, yet in this group the overall response rate was 17.6%, with a median survival time of 4.6 to 6.1 months in 118 patients. Clinical trails in previously treated patients with non-small cell and small cell lung cancer are warranted.